Dr. Chloé Dubois

Oncology pharmacist · UCLH · United Kingdom (GB) · Oncology

Tier 3STK-0010GoodOwner MSL RARachel Adeyemi

Data minimisation

Consent status: Recorded. The name shown may be a pseudonym. Contact details, personal identifiers and remuneration fields are hidden for your role; only scientific-profile fields needed for engagement planning are displayed.

Specialty: Thoracic oncology
Disease interests: NSCLC
Scientific interests: Immunotherapy sequencing
Engagement preference: Virtual
Advisory boards: 0
Publications: 11
Source system: Veeva CRM
Data quality: Good

Engagement plan

Cadence target for Tier 3: 1 per year (assumption)

Last engaged: 14 Sept 2026 (yesterday)
Next planned contact: 14 Sept 2027
Last 6 months vs target: 100%
2 of 1 expected engagements

Insights from this stakeholder (1)

INS-0061Infusion-reaction management
14 Sept 2026 · Medical-information need
HighSubmitted

Engagement history (2)

All engagements including drafts, newest first

Date	Type	Format	MSL	Product	Topics	Insights	Flags	Status
14 Sept 2026	Scientific exchange	Virtual	Rachel Adeyemi	Vantrexa	Infusion-reaction management	1	MI request	Submitted	ENG-0002
09 Aug 2026	Payer / HTA meeting	In person	James Whitfield	Vantrexa	Sequencing after progressionDuration of response	0	MI request	Reviewed	ENG-0057

Timeline

14 Sept 2026
Scientific exchange
Infusion-reaction management
09 Aug 2026
Payer / HTA meeting
Sequencing after progression, Duration of response

Related stakeholders (7)

UCLH

Dr. William Vogel
Pathologist
Tier 3
Dr. Benedikt Lopez
Pathologist
Tier 3
Dr. Zoë Castellano
Renal pathologist
Tier 2
Dr. Daniel Kimura
Academic nephrologist
Tier 2
Dr. Tomoko Jensen
Renal pathologist
Tier 2
Dr. Gabriel Kimura
Dermatologist
Tier 1
Dr. Javier Tanaka
Dermatologist
Tier 3